|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM234A |
Gene summary for FAM234A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM234A | Gene ID | 83986 |
| Gene name | family with sequence similarity 234 member A | |
| Gene Alias | C16orf9 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9H0X4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83986 | FAM234A | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.24e-07 | 3.82e-01 | -0.1808 |
| 83986 | FAM234A | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.49e-06 | 4.86e-01 | -0.0811 |
| 83986 | FAM234A | HTA11_347_2000001011 | Human | Colorectum | AD | 9.19e-09 | 3.48e-01 | -0.1954 |
| 83986 | FAM234A | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.25e-03 | 3.67e-01 | -0.1207 |
| 83986 | FAM234A | HTA11_83_2000001011 | Human | Colorectum | SER | 5.09e-03 | 3.82e-01 | -0.1526 |
| 83986 | FAM234A | HTA11_866_2000001011 | Human | Colorectum | AD | 7.25e-03 | 2.02e-01 | -0.1001 |
| 83986 | FAM234A | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.51e-10 | 4.35e-01 | -0.059 |
| 83986 | FAM234A | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.48e-03 | 5.19e-01 | -0.0177 |
| 83986 | FAM234A | A015-C-203 | Human | Colorectum | FAP | 2.76e-04 | -1.48e-01 | -0.1294 |
| 83986 | FAM234A | A015-C-006 | Human | Colorectum | FAP | 1.72e-02 | -2.13e-01 | -0.0994 |
| 83986 | FAM234A | A015-C-104 | Human | Colorectum | FAP | 2.28e-02 | -1.02e-01 | -0.1899 |
| 83986 | FAM234A | A002-C-116 | Human | Colorectum | FAP | 2.94e-04 | -1.52e-01 | -0.0452 |
| 83986 | FAM234A | LZE4T | Human | Esophagus | ESCC | 5.87e-05 | 5.47e-02 | 0.0811 |
| 83986 | FAM234A | LZE7T | Human | Esophagus | ESCC | 9.47e-04 | 4.42e-01 | 0.0667 |
| 83986 | FAM234A | LZE8T | Human | Esophagus | ESCC | 2.56e-05 | 3.26e-01 | 0.067 |
| 83986 | FAM234A | LZE20T | Human | Esophagus | ESCC | 4.39e-09 | 2.24e-01 | 0.0662 |
| 83986 | FAM234A | LZE21D1 | Human | Esophagus | HGIN | 4.61e-02 | 2.23e-01 | 0.0632 |
| 83986 | FAM234A | LZE22T | Human | Esophagus | ESCC | 6.60e-03 | 3.58e-01 | 0.068 |
| 83986 | FAM234A | LZE24T | Human | Esophagus | ESCC | 3.81e-13 | 3.13e-01 | 0.0596 |
| 83986 | FAM234A | LZE21T | Human | Esophagus | ESCC | 3.32e-05 | 4.21e-01 | 0.0655 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM234A | SNV | Missense_Mutation | rs758150908 | c.1282N>A | p.Ala428Thr | p.A428T | Q9H0X4 | protein_coding | deleterious(0) | benign(0.437) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| FAM234A | SNV | Missense_Mutation | c.331C>G | p.Leu111Val | p.L111V | Q9H0X4 | protein_coding | tolerated(0.22) | benign(0.203) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| FAM234A | deletion | Frame_Shift_Del | novel | c.1473_1474delNN | p.Ala492ArgfsTer38 | p.A492Rfs*38 | Q9H0X4 | protein_coding | TCGA-A2-A25F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| FAM234A | insertion | Frame_Shift_Ins | novel | c.813_814insCATCT | p.Gly272HisfsTer20 | p.G272Hfs*20 | Q9H0X4 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| FAM234A | insertion | In_Frame_Ins | novel | c.1059_1060insTCCCCAAGAATGGTGGAGTACACACTTCCCATTTGTGCT | p.Leu353_Asp354insSerProArgMetValGluTyrThrLeuProIleCysAla | p.L353_D354insSPRMVEYTLPICA | Q9H0X4 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| FAM234A | SNV | Missense_Mutation | novel | c.1617C>G | p.Ile539Met | p.I539M | Q9H0X4 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| FAM234A | SNV | Missense_Mutation | novel | c.1617N>G | p.Ile539Met | p.I539M | Q9H0X4 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM234A | SNV | Missense_Mutation | c.481G>C | p.Glu161Gln | p.E161Q | Q9H0X4 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM234A | SNV | Missense_Mutation | c.1408N>C | p.Glu470Gln | p.E470Q | Q9H0X4 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| FAM234A | SNV | Missense_Mutation | c.983N>C | p.Val328Ala | p.V328A | Q9H0X4 | protein_coding | tolerated(0.08) | benign(0.292) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |